التفاصيل البيبلوغرافية
| العنوان: |
Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation |
| المؤلفون: |
Xia, Yue Yin, Gronwald, Jacek, Karlan, Beth, Lubinski, Jan, McCuaig, Jeanna M, Brooks, Jennifer, Moller, Pal, Eisen, Andrea, Sun, Sophie, Senter, Leigha, Bordeleau, Louise, Neuhausen, Susan L, Singer, Christian F, Tung, Nadine, Foulkes, William D, Sun, Ping, Narod, Steven A, Kotsopoulos, Joanne, Yerushalmi, Rinat, Fruscio, Robert, Rastelli, Antonella, Zovato, Stefania, Hyder, Zerin, Huzarski, Tomasz, Cybulski, Cezary, Sweet, Kevin, Wood, Marie, McKinnon, Wendy, Elser, Christine, Pal, Tuya, Wiesner, Georgia, Friedman, Eitan, Meschino, Wendy, Snyder, Carrie, Metcalfe, Kelly, Poll, Aletta, Gojska, Nicole, Warner, Ellen, Kim, Raymond H, Rosen, Barry, Demsky, Rochelle, Ainsworth, Peter, Panabaker, Karen, Steele, Linda, Saal, Howard, Serfas, Kim, Panchal, Seema, Cullinane, Carey A, Reilly, Robert E, Blum, Joanne L, Kwong, Ava, Rayson, Daniel, Isaacs, Claudine, Ramón y Cajal, Teresa, Dungan, Jeffrey, Cohen, Stephanie |
| المصدر: |
Gynecologic Oncology, vol 164, iss 3 |
| بيانات النشر: |
eScholarship, University of California |
| سنة النشر: |
2022 |
| المجموعة: |
University of California: eScholarship |
| مصطلحات موضوعية: |
Reproductive Medicine, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Breast Cancer, Clinical Research, Prevention, Contraception/Reproduction, Cancer, Ovarian Cancer, 2.2 Factors relating to the physical environment, Aetiology, Reproductive health and childbirth, Good Health and Well Being, BRCA1 Protein, BRCA2 Protein, Breast Neoplasms, Carcinoma, Ovarian Epithelial, Case-Control Studies, Contraceptives, Oral, Female, Heterozygote, Humans, Mutation, Ovarian Neoplasms, Risk Factors, BRCA, Contraception |
| جغرافية الموضوع: |
514 - 521 |
| الوصف: |
Background BRCA1 and BRCA2 (BRCA) mutation carriers face a high lifetime risk of developing ovarian cancer. Oral contraceptives are protective in this population; however, the impact of other types of contraception (e.g. intrauterine devices, implants, injections) is unknown. We undertook a matched case-control study to evaluate the relationship between type of contraception and risk of ovarian cancer among women with BRCA mutations. Methods A total of 1733 matched pairs were included in this analysis. Women were matched according to year of birth, date of study entry, country of residence, BRCA mutation type and history of breast cancer. Detailed information on hormonal, reproductive and lifestyle exposures were collected from a routinely administered questionnaire. Conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) associated with each contraceptive exposure. Results Ever use of any contraceptive was significantly associated with reduced risk of ovarian cancer (OR=0.62; 95% CI 0.52-0.75; P<0.0001), which was driven by significant inverse associations with oral contraceptives (OR=0.66; 95% CI 0.54-0.79; P<0.0001) and contraceptive implants (OR=0.30; 95% CI 0.12-0.73; P=0.008). We observed a similar effect with use of injections (OR=0.37; 95% CI 0.10-1.38; P=0.14), but this did not achieve significance. No significant associations were observed between patterns of intrauterine device use and risk of ovarian cancer. Conclusions These findings support a protective effect of oral contraceptives and implants on risk of ovarian cancer among women with BRCA mutations. The possible protective effect of injections requires further evaluation. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
unknown |
| العلاقة: |
qt9b55w1xj; https://escholarship.org/uc/item/9b55w1xjTest |
| الإتاحة: |
https://escholarship.org/uc/item/9b55w1xjTest |
| حقوق: |
CC-BY |
| رقم الانضمام: |
edsbas.EBBEAB |
| قاعدة البيانات: |
BASE |
